For local public health agencies and healthcare providers only:
For general questions about COVID-19:
May 13, 2022: Potentially Significant Drug Interactions, including Contraindicated Drugs (PAXLOVIDTM)
March 14, 2022: Oral COVID-19 medication
December 29, 2021: Federal CMS guidance on omnibus COVID-19 health care staff vaccination interim final rule
December 21, 2021: Pfizer Vaccine Shelf-Life Extension
December 20, 2021: Increase in vaccine reimbursement for Health First Colorado Medicaid members
December 15, 2021: Virtual Grand Rounds: The latest on Omicron and Crisis Standards of Care
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.